Lr-103

EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

Virtual Booth

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

1 API Suppliers, 1 USDMF

1 API Suppliers
1 USDMF

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

0 DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: Lr-103, 156316-85-7, 2900i92z36, (24s)-1alpha,24-dihydroxyvitamin d2 / (24s)-1alpha,24-dihydroxyergocalciferol, (5z,7e,22e)-(1s,3r,24s)-9,10-seco-5,7,10(19),22-ergostatetraene-1,3,24-triol, Unii-2900i92z36

Molecular Formula

C₂₈H₄₄O₃

Molecular Weight

428.6 g/mol

InChI Key

ODZFJAXAEXQSKL-WRJREGAQSA-N

FDA UNII

2900I92Z36

LR-103 is a naturally occurring D-hormone that is produced by the kidneys from vitamin D. LR-103 is one of the D-hormones produced from Hectorol. It is developed for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease (CKD). Studies have shown LR-103 has the same potency as calcitriol, but much lower toxicity.

1 2D Structure

Lr-103

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

(1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-5-hydroxy-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol

2.1.2 InChI

InChI=1S/C28H44O3/c1-18(2)28(6,31)15-13-19(3)24-11-12-25-21(8-7-14-27(24,25)5)9-10-22-16-23(29)17-26(30)20(22)4/h9-10,13,15,18-19,23-26,29-31H,4,7-8,11-12,14,16-17H2,1-3,5-6H3/b15-13+,21-9+,22-10-/t19-,23-,24-,25+,26+,27-,28-/m1/s1

2.1.3 InChI Key

ODZFJAXAEXQSKL-WRJREGAQSA-N

2.1.4 Canonical SMILES

CC(C)C(C)(C=CC(C)C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C)O

2.1.5 Isomeric SMILES

C[C@H](/C=C/[C@](C)(C(C)C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](C[C@@H](C3=C)O)O)C

2.2 Other Identifiers

2.2.1 UNII

2900I92Z36

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 1,24(s)-dihydroxyvitamin D2

2. 1,24-dihydroxyvitamin D2

3. 1alpha,24(s)(oh)2d2

4. 1alpha,24(s)-dihydroxyvitamin D2

5. Lr-103

2.3.2 Depositor-Supplied Synonyms

1. Lr-103

2. 156316-85-7

3. 2900i92z36

4. (24s)-1alpha,24-dihydroxyvitamin D2 / (24s)-1alpha,24-dihydroxyergocalciferol

5. (5z,7e,22e)-(1s,3r,24s)-9,10-seco-5,7,10(19),22-ergostatetraene-1,3,24-triol

6. Unii-2900i92z36

7. Lmst03010062

8. 1alpha,24(s)-dihydroxyergocalciferol

9. Schembl3026089

10. Lr 103 [who-dd]

11. Dtxsid801015488

12. Zinc4791507

13. Db06117

14. (1alpha,3beta,5z,7e,22e,24s)-9,10-secoergosta-5,7,10(19),22-tetraene-1,3,24-triol

15. 1.alpha.,24s-dihydroxyvitamin D2

16. 1.alpha.,24(s)-dihydroxyergocalciferol

17. Q27254357

18. (1.alpha.,3.beta.,5z,7e,22e,24s)-9,10-secoergosta-5,7,10(19),22-tetraene-1,3,24-triol

19. 9,10-secoergosta-5,7,10(19),22-tetraene-1,3,24-triol,(1.alpha.,3.beta.,5z,7e,22e)-

2.4 Create Date

2006-08-30

3 Chemical and Physical Properties

Molecular Formula	C₂₈H₄₄O₃
Molecular Weight	428.6 g/mol
XLogP3	5.1
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	3
Rotatable Bond Count	5
Exact Mass	428.32904526 g/mol
Monoisotopic Mass	428.32904526 g/mol
Topological Polar Surface Area	60.7 Å²
Heavy Atom Count	31
Formal Charge	0
Complexity	760
Isotope Atom Count	0
Defined Atom Stereocenter Count	7
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	3
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

Investigated for use/treatment in parathyroid disorders.

5 Pharmacology and Biochemistry

5.1 Pharmacology

LR-103 is effective in normalizing serum calcium and PTH levels without causing hypercalcemia. Importantly, LR-103 also normalized bone abnormalities consequent to SHPT and active vitamin D deficiency.

API SUPPLIERS